Russian Heart Failure Journal 2012year Ultraselective beta-blockers in treatment of AH patients with high cardiovascular risk: estimation of the influence on major risk factors and quality of life


To access this material please log in or register

Register Authorize
2012/№4

Ultraselective beta-blockers in treatment of AH patients with high cardiovascular risk: estimation of the influence on major risk factors and quality of life

Mamedov M. N.
Federal State Budgetary Institution, “National Research Center for Preventive Medicine” of the RF Ministry of Health Care, Petroverigsky Per. 10, Bldg. 3, Moscow 101990

Keywords: arterial hypertension, beta-blockers, cardiovascular risk

DOI: 10.18087/rhfj.2012.4.1694

Relevance. Antihypertensive effect of Bisoprolol in a separate group of patients with AH and high cardiovascular risk is poorly studied. The data about metabolic effects of Bisoprolol and its influence on the quality of life is inconsistent. Objective. Estimate effect of generic Bisoprolol on hemodynamic parameters, main RF and the quality of life of patients with AH and high cardiovascular risk. Materials and methods. 24 patients were enrolled in the 14 week open-label clinical study, age 40–60 years, with AH and high cardiovascular risk. Before Bisoprolol administration (Biol, Sandoz) 5–10 mg, patients’ BP and HR were measured, electrocardiogram at rest was recorded, total cholesterol, triglyceride, glucose, uric acid in blood, as well as the quality of life. Results. Against the therapy SBP decreased by 22 %, DBP by 10 %. In 18 of 24 patients with AH and high cardiovascular risk, target levels of BP (SBP <140 mm Hg and / or DBP<90 mm Hg) were reached. Bisoprolol course promoted significant decrease of HR by 24 %. Blood concentration of total cholesterol, triglyceride, glucose and uric acid against Bisoprolol therapy remained without changes. Against Bisoprolol therapy, some improvement of the quality of life was noted. Conclusion. Generic Bisoprolol monotherapy within 14 weeks with daily dose 5–10 mg had antihypertensive and neutral metabolic effect, as well as improvement of some quality-of-life indices in patients with AH and high cardiovascular risk.
  1. Messserli F. H., editor. The ABC’s of Antihypertensive Therapy. – New York: Raven Press; 1994.
  2. Mancia G, De Backer G, Dominiczak A et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25 (6):1105–1187.
  3. Национальные клинические рекомендации. Сборник. Под ред. Оганова Р. Г., 2‑е издание. – М.: Изд-во «Силицея–Полиграф», 2009. – 528 с.
  4. Чазов Е. И., Чазова И. Е. (ред.) Руководство по артериальной гипертонии. – М.: «Медиа Медика», 2005. – 734с.
  5. Лукина Ю. В., Марцевич С. Ю. Бисопролол – высокоселективный бета-адреноблокатор с позиции доказательной медицины. Рациональная фармакотерапия в кардиологии. 2010;6 (1):103–107.
  6. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http://www.accessdata.fda.gov / scripts / cder / ob / default.cfm
  7. Чазова И. Е., Мычка В. Б. Метаболический синдром. – М.: Media Medica, 2004. – 164 с.
  8. Небиеридзе Д. В., Оганов Р. Г. Метаболические и сосудистые эффекты антигипертензивной терапии. – М.: «Универсум Паблишинг», 2005. – 104.
Mamedov M. N. Ultraselective beta-blockers in treatment of AH patients with high cardiovascular risk: estimation of the influence on major risk factors and quality of life. Russian Heart Failure Journal. 2012;13(4):237-240

To access this material please log in or register

Register Authorize
Ru En